KRAS and Immunodeficiency: The main drivers include secondary mutations of KRAS itself, reactivation of multiple MAPK effectors from upstream and downstream of KRAS, immunodeficiency, etc. Combination therapy is currently an effective means to overcome drug resistance, and more cost-effective methods need to be explored.